ADH8 Antibody

What is ADH8 antibody and what target does it recognize?

ADH8 antibody recognizes alcohol dehydrogenase iron-containing protein 1 (ADHFE1), an enzyme involved in oxidative processes. ADH8 is commonly used as a synonym for ADHFE1 in research contexts, along with other names including Fe-containing alcohol dehydrogenase, hydroxyacid-oxoacid transhydrogenase, and HOT . The ADHFE1 gene encodes hydroxyacid-oxoacid transhydrogenase (EC 1.1.99.24), which is responsible for the oxidation of 4-hydroxybutyrate in mammalian tissues . Understanding this target is crucial when selecting appropriate antibodies for specific research applications.

What experimental applications are suitable for ADH8/ADHFE1 antibodies?

ADH8/ADHFE1 antibodies can be employed across multiple laboratory techniques depending on the specific clone and formulation:

Selection should be based on the specific research question and experimental design requirements .

What species reactivity is available for ADH8/ADHFE1 antibodies?

Different ADH8/ADHFE1 antibodies exhibit varied species reactivity profiles:

• Human-specific antibodies: Some monoclonal antibodies like EPR12501 react specifically with human samples and do not cross-react with mouse or rat samples .

• Multi-species reactive antibodies: Several polyclonal antibodies demonstrate reactivity across human, mouse, and rat samples .

When designing cross-species experiments, carefully evaluate the antibody's validated reactivity profile to ensure appropriate species coverage .

How should ADH8/ADHFE1 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling of ADH8/ADHFE1 antibodies is critical for maintaining functionality:

• Short-term storage: Maintain at 2-8°C for up to 2 weeks .

• Long-term storage: Store at -20°C in small aliquots (no less than 20 μl) to prevent freeze-thaw cycles .

• Buffer conditions: Most formulations contain preservatives such as 0.01-0.05% sodium azide and stabilizers like glycerol (typically 40%) .

• Avoid repeated freeze-thaw cycles as these significantly diminish antibody activity and specificity .

Researchers should follow manufacturer-specific recommendations as buffer compositions may vary between suppliers and influence antibody performance .

What controls should be included when using ADH8/ADHFE1 antibodies?

Rigorous experimental design requires appropriate controls:

• Positive tissue controls: Human fetal liver and fetal kidney lysates have been validated as positive controls for certain ADH8/ADHFE1 antibodies .

• Negative controls: Include samples known to lack the target protein or use tissues from knockout models when available.

• Isotype controls: Use matched isotype antibodies (e.g., IgG, IgG1 κ, IgG2a κ) to control for non-specific binding .

• Loading controls: For Western blotting, include housekeeping proteins to normalize protein loading.

Implementing these controls helps validate experimental findings and identifies potential non-specific binding issues .

How can researchers validate the specificity of ADH8/ADHFE1 antibodies?

Antibody validation is crucial for ensuring experimental reliability:

• Multiple antibody approach: Use different antibodies targeting distinct epitopes of ADH8/ADHFE1 .

• Knockout/knockdown validation: Compare staining between wild-type and ADHFE1 knockout/knockdown samples (CRISPR knockout systems are available) .

• Immunoprecipitation-Mass Spectrometry: Confirm antibody pulls down the correct target protein.

• Peptide competition assays: Pre-incubate antibody with immunizing peptide to demonstrate specificity.

• Cross-reactivity testing: Evaluate binding to similar proteins, particularly other alcohol dehydrogenase family members.

This multi-pronged approach helps establish confidence in antibody specificity, particularly important given that autoantibodies can occur naturally in healthy individuals .

What are the optimal conditions for immunoprecipitation using ADH8/ADHFE1 antibodies?

Immunoprecipitation requires careful optimization:

• Antibody selection: Choose antibodies specifically validated for IP applications (e.g., ADHFE1 antibody EPR12501) .

• Antibody amount: Typically 1-5 μg of antibody per 100-500 μg of total protein lysate.

• Lysate preparation: Use appropriate lysis buffers with protease inhibitors to maintain protein integrity.

• Binding conditions: Incubate antibody with lysate overnight at 4°C with gentle rotation.

• Bead selection: Protein A or G beads depending on antibody isotype (Protein A for rabbit IgG, Protein G for mouse IgG) .

• Washing conditions: Multiple stringent washes to remove non-specific binding.

Successful IP experiments may require optimization of these parameters for specific experimental conditions .

How do epitope characteristics affect ADH8/ADHFE1 antibody performance?

The epitope recognized by an ADH8/ADHFE1 antibody significantly influences its performance:

• Epitope location: Antibodies targeting amino acids 20-259 of human ADHFE1 (as with F-9 and B-10 clones) may perform differently than those targeting other regions .

• Epitope accessibility: Consider whether the epitope is exposed in native conditions or only in denatured states.

• Post-translational modifications: These can mask epitopes or alter antibody binding affinity.

• Epitope conservation: For cross-species experiments, target epitopes conserved across species.

• Structural characteristics: As noted in research on autoantigens, properties like hydrophilicity, basicity, aromaticity, and flexibility can influence antibody binding .

Understanding these characteristics helps in selecting the appropriate antibody for specific applications and experimental conditions .

How can researchers address non-specific binding with ADH8/ADHFE1 antibodies?

Non-specific binding can compromise experimental results. Address this issue through:

• Optimization of blocking conditions: Test different blocking agents (BSA, non-fat milk, normal serum) at various concentrations.

• Antibody dilution optimization: Titrate antibody concentrations to determine optimal signal-to-noise ratio.

• Buffer modification: Adjust salt concentration or add detergents to reduce non-specific interactions.

• Secondary antibody controls: Include controls omitting primary antibody to identify secondary antibody non-specific binding.

• Pre-adsorption: Consider pre-adsorbing antibodies with tissue or cell lysates lacking target protein.

These approaches can significantly improve signal specificity and experimental reproducibility .

How should researchers interpret conflicting results from different ADH8/ADHFE1 antibody clones?

Discrepancies between antibody clones require methodical investigation:

• Epitope differences: Different clones recognize distinct epitopes that may be differentially accessible in various experimental conditions .

• Antibody format variation: Monoclonal versus polyclonal antibodies provide different specificity and sensitivity profiles .

• Application-specific performance: Antibodies optimized for Western blotting may not perform well in immunohistochemistry .

• Validation strategies: Implement orthogonal techniques (e.g., mass spectrometry, genetic approaches) to resolve conflicting results.

• Isoform recognition: Consider whether antibodies detect different protein isoforms or post-translationally modified variants.

When faced with discrepancies, researchers should evaluate the validation data for each antibody and consider using multiple detection methods to confirm findings .

What considerations are important when selecting between monoclonal and polyclonal ADH8/ADHFE1 antibodies?

The choice between monoclonal and polyclonal antibodies involves several research-specific considerations:

Recombinant monoclonal antibodies offer advantages including high batch-to-batch consistency, improved sensitivity and specificity, long-term security of supply, and animal-free production .

What are the recommended approaches for using ADH8/ADHFE1 antibodies in multiplex immunofluorescence?

Multiplex immunofluorescence with ADH8/ADHFE1 antibodies requires careful planning:

• Antibody host species selection: Choose primary antibodies from different host species to avoid cross-reactivity of secondary antibodies.

• Fixation optimization: Different antibodies may require specific fixation protocols (e.g., 4% paraformaldehyde) .

• Sequential staining: Consider sequential rather than simultaneous incubation when using multiple antibodies.

• Spectral compatibility: Select fluorophores with minimal spectral overlap.

• Signal amplification: For low-abundance targets, consider tyramide signal amplification or other amplification methods.

When working with multiple markers, staining optimization should be performed for each antibody individually before combining them .

How can researchers leverage ADH8/ADHFE1 antibodies in studies of autoimmunity?

ADH8/ADHFE1 antibodies can provide insights into autoimmune processes:

• Autoantibody profiling: Research has shown that healthy individuals naturally possess autoantibodies, including those against metabolic enzymes .

• Epitope mapping: Understanding shared epitopes between autoantigens can help identify molecular mimicry .

• Tissue expression analysis: Consider that several autoantigens are sequestered from circulating autoantibodies, which may be relevant for ADHFE1 as a mitochondrial protein .

• Age-related changes: The number of autoantibodies increases with age, plateauing around adolescence, which may affect baseline measurements .

• Gender considerations: While some autoantibodies show gender bias, this should be evaluated specifically for ADH8/ADHFE1 .

This research direction may provide valuable insights into both normal immune function and pathological conditions .

What cutting-edge technologies can be combined with ADH8/ADHFE1 antibodies for advanced research?

Integrating ADH8/ADHFE1 antibodies with emerging technologies enables novel research approaches:

• CRISPR/Cas9 systems: ADHFE1 CRISPR knockout, HDR, and double nickase plasmids are available for genetic manipulation studies .

• CRISPR activation products: ADHFE1 CRISPR activation plasmids and lentiviral activation particles enable gene activation studies .

• ChIP-seq applications: Some antibodies may be suitable for chromatin immunoprecipitation sequencing to study protein-DNA interactions .

• CUT&RUN assays: This technique offers higher resolution than traditional ChIP for studying protein-DNA interactions .

• Computational modeling: Advances in computational approaches for antibody specificity can enhance experimental design and interpretation .

These advanced technologies can significantly expand the research applications of ADH8/ADHFE1 antibodies beyond traditional methods .

How might ADH8/ADHFE1 research contribute to understanding disease mechanisms?

Research using ADH8/ADHFE1 antibodies has potential implications for various disease states:

• Cancer research: ADHFE1 expression has been studied in different cancer types, including liver and lung cancer .

• Metabolic disorders: Given its role in 4-hydroxybutyrate metabolism, ADHFE1 may be relevant in metabolic disease research .

• Neurodegenerative conditions: The oxidative properties of ADHFE1 may relate to oxidative stress in neurodegeneration, potentially linking to research on monoclonal antibodies for treating conditions like Alzheimer's disease .

• Autoimmune conditions: Understanding the role of natural autoantibodies against metabolic enzymes like ADHFE1 could provide insights into autoimmune mechanisms .

Future research may explore these connections using increasingly sophisticated antibody-based approaches .

What methodological advances are improving antibody design and characterization?

Recent innovations in antibody technology are enhancing research capabilities:

• Inference and design approaches: Computational methods now enable the design of antibodies with customized specificity profiles .

• High-throughput sequencing: Integration with computational analysis allows for better control over antibody specificity .

• Binding mode identification: New approaches can disentangle different binding modes associated with chemically similar ligands .

• Recombinant production: Animal-free recombinant antibody production improves batch-to-batch consistency and reproducibility .

• Biophysics-informed modeling: Combination with selection experiments allows for design of proteins with desired physical properties .

These advances enable researchers to develop antibodies with precise characteristics for specialized applications .

What best practices should researchers follow when publishing research using ADH8/ADHFE1 antibodies?

To ensure reproducibility and transparency in antibody-based research:

• Complete antibody documentation: Report catalog number, clone ID, lot number, supplier, and RRID (Research Resource Identifier) when available .

• Validation evidence: Include details of how antibody specificity was verified for the particular application.

• Experimental conditions: Document precise dilutions, incubation times, temperatures, and buffer compositions.

• Controls: Clearly describe all controls used, including positive, negative, and isotype controls.

• Images and quantification: Provide representative images showing both positive and negative staining, with appropriate scale bars and quantification methods.